Axsome Therapeutics has the GF Score of 52, which implies that the company
might have
Poor future performance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Axsome Therapeutics
might have
Poor future performance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Axsome Therapeutics GF Score Related Terms
AXSM vs MDGL, IONS, BMRN: GF Score Comparison
For the Biotechnology subindustry, Axsome Therapeutics's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Axsome Therapeutics GF Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Axsome Therapeutics's GF Score distribution charts can be found below:
* The bar in red indicates where Axsome Therapeutics's GF Score falls into.
Axsome Therapeutics (AXSM) has a GF Score of 52 as of Jul. 07, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Axsome Therapeutics and its competitors. This is 49% above median its historical median of 35.00. Over the past decade, Axsome Therapeutics' GF Score has ranged from 16.00 to 60.00.
Is Axsome Therapeutics' GF Score too high?
Axsome Therapeutics' current GF Score of 52 is 49% above median its 10-year median of 35.00. Over the past 10 years, this metric has ranged from a low of 16.00 to a high of 60.00. Overall, Axsome Therapeutics has a GF Score™ of 52/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Axsome Therapeutics' GF Score compare to MDGL and IONS?
Axsome Therapeutics' GF Score of 52 can be compared against companies in the Biotechnology industry. Historically, Axsome Therapeutics' own GF Score has ranged from 16.00 to 60.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Axsome Therapeutics and its competitors. Axsome Therapeutics's current GF Score is 52, which is 49% above median its own 10-year median of 35.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Axsome Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Axsome Therapeutics (AXSM) is currently considered Modestly Overvalued. The stock's GF Value™ is $223.22, compared to a current price of $249.76 — trading 11.9% above its estimated fair value. The current GF Score is 52, which is 49% above median its 10-year median of 35.00. Axsome Therapeutics' overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Axsome Therapeutics (AXSM), the current GF Score is 52 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Axsome Therapeutics (AXSM) Overvalued in 2026?
Based on GuruFocus' analysis, Axsome Therapeutics stock appears to be overvalued.
The current stock price of $249.76 is trading 11.9% above its estimated GF Value™ of $223.22.
GuruFocus considers Axsome Therapeutics to be Modestly Overvalued.
Key valuation signals for AXSM:
GF Score: 52 (49% above median its 10-year median of 35.00)
GF Value™: $223.22 vs. price of $249.76 (11.9% above fair value)
No single metric tells the full story. See the AXSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
52GF Score
Get the complete analysis for AXSM
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AXSM has been successfully added to your 